Variational AI, a Vancouver, BC, Canada-based developer of a foundation model for small molecule drug discovery, raised $5.5M in Seed extension funding.
The round was led by Nimbus Synergies, with participation from Merck Global Health Innovation Fund, Quimby Investments, Threshold Impact, Defined Capital and existing investors Flying Fish, A&E Investment, and Nepenthe Capital.
The company intends to use the funds to bring its technology to a broader market, helping biopharmaceutical companies design novel drugs faster and more efficiently.
Led by CEO Handol Kim, Variational AI is improving the unit economics of drug discovery through the generative AI. The founding machine learning (ML) team, whose members come from AI research labs at Google, Microsoft, MIT, Caltech, and D-Wave Quantum, developed Enki™, a foundation model for small molecule drug discovery, which empowers biopharmaceutical chemistry teams to efficiently discover and optimize novel hits and leads, accelerating early-stage drug discovery.
FinSMEs
20/02/2025